Roles of serum microRNA-122 and microRNA-155 in patients with chronic hepatitis B

doi:10.3969/j.issn.1673-8640.2019.08.004

Abstract

Abstract:

Objective To analyze the relationship between serum levels of microRNA-122（miRNA-122）,microRNA-155（miRNA-155） and viral replication,antiviral therapy and drug resistance gene mutation in patients with chronic hepatitis B（CHB）. Methods A total of 24 healthy subjects and 35 patients with CHB were enrolled. Serum levels of miRNA-122,miRNA-155,hepatitis B virus（HBV） DNA load,hepatitis B surface antigen（HBsAg）,hepatitis B surface antibody（HBsAb）,hepatitis B e antigen（HBeAg）,hepatitis B e antibody（HBeAb）,hepatitis B core antibody（HBcAb）,alanine aminotransferase（ALT）,the drug resistance gene mutation of HBV and the genotyping of HBV were determined,and the correlations were analyzed. Results In CHB group,serum level of miRNA-122 was higher,and serum level of miRNA-155 was lower than those in healthy control group（P<0.05）. Spearman correlation analysis showed that the relative expression of serum miRNA-122 in CHB patients without antiviral treatment with nucleoside drugs（non-treatment group,18 cases） was positively correlated with the pattern of hepatitis B serological markers（r=0.73,P=0.00）,it was positively correlated with HBV DNA load,HBsAg,HBeAg and ALT in non-treatment group（r=0.69,0.74,0.53 and 0.48,respectively,P<0.05）,and it was negatively with age（r=-0.58,P=0.01）. In treatment group（17 cases）,the relative expression of serum miRNA-122 was positively correlated with the level of HBsAg（r=0.54,P<0.05）,while the relative expression of serum miRNA-155 was correlated with HBV DNA load（r=-0.54,P<0.05）. CHB group was subclassified into HBV DNA negative group and HBV DNA positive group according to whether HBV DNA was detemined or not. The relative expression of serum miRNA-155 in HBV DNA positive group was lower than that in HBV DNA negative group（P<0.05）. Conclusions Serum miRNA-122 is correlated with HBV DNA load,HBsAg,HBeAg and ALT,and it may predict viral replication and severity of CHB. Serum miRNA-155 may be valuable in predicting and evaluating the therapeutic effect of CHB.

Key words: MicroRNA-122, MicroRNA-155, Chronic hepatitis B

CLC Number:

R446.1

WANG Yingzhi, LIU Hua, WANG Wenjuan, GAO Feng, YANG Cuixia. Roles of serum microRNA-122 and microRNA-155 in patients with chronic hepatitis B[J]. Laboratory Medicine, 2019, 34(8): 691-695.

Figures/Tables 2

References 9

[1]	LATERZA O F,LIM L,GARRETT-ENGELE P W,et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury[J]. Clin Chem,2009,55(11):1977-1983.
[2]	中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎诊断标准(2015年版)[J]. 中西医结合肝病杂志,2015,25(6):384.
[3]	NAKAMURA M,KANDA T,JIANG X,et al.Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis[J]. PLoS One,2017,12(5): e0177302.
[4]	TAT TRUNG N,DUONG D C,TONG H V,et al.Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma[J]. PLoS One,2018,13(4):e0196081.
[5]	QIAO D D,YANG J,LEI X F,et al.Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features[J]. Eur Rev Med Pharmacol Sci,2017,21(4):742-747.
[6]	AKUTA N,SUZUKI F,KOBAYASHI M,et al.Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance[J]. J Med Virol,2018,90(10):1586-1592.
[7]	SARKAR N,PANIGRAHI R,PAL A,et al.Expression of microRNA-155 correlates positively with the expression of Toll-like receptor 7 and modulates hepatitis B virus via C/EBP-β in hepatocytes[J]. J Viral Hepat,2015,22(10):817-827.
[8]	YU S L,DENG H,LI X H,et al.Expression of microRNA-155 is downregulated in peripheral blood mononuclear cells of chronic hepatitis B patients[J]. Hepat Mon, 2016,16(1):e34483.
[9]	BALA S,TILAHUN Y,TAHA O,et al.Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection[J]. J Transl Med,2012,10:151.

[1]	LIU Yang, GENG Kunjing, LI Hongjiang, SHI Haoxi, CHEN Sisi. Relationship of 25（OH）D₃ and liver inflammatory stage with the efficacy of antiviral therapy [J]. Laboratory Medicine, 2022, 37(7): 628-631.
[2]	MA Yanting, SU Xi, HUANG Fei, WANG Mengxian, SHEN Minna, ZHANG Chunyan, WANG Beili, PAN Baishen, GUO Wei. Clinical role of HBV RNA detection in chronic hepatitis B [J]. Laboratory Medicine, 2022, 37(1): 72-77.
[3]	LI Caidong, ZHANG Xuqiang, LEI Zhiping, CHEN Qiaoli, CHEN Lu, TIAN Pengfei, DUAN Zhengjun. Clinical values of IL-1β,IL-6 and TNF-α in different clinical courses of chronic HBV infection [J]. Laboratory Medicine, 2021, 36(8): 790-794.
[4]	LIU Tingting, LIN Yuting, Mila , LI Xiaoqin. Correlation between serum IL-33 level and its gene polymorphism and the clinical outcome of HBV infection [J]. Laboratory Medicine, 2021, 36(11): 1101-1105.
[5]	GUO Ping, ZHUANG Lihua, CHEN Liting, WANG Jianbiao, WU Jianfeng. Roles of MCV,RDW and SAA in the progression of chronic hepatitis B [J]. Laboratory Medicine, 2020, 35(11): 1153-1157.
[6]	YU Xiaochun, HU Xujiao, ZHANG Jiaqing, GUO Leilei. Roles of HA,Ⅳ-C,APRI and Fib-4 in the diagnosis of hepatitis B-related liver fibrosis [J]. Laboratory Medicine, 2019, 34(6): 539-542.
[7]	GAO Wanqin, ZHANG Qin, ZHU Lin, WU Bin, HE Wentao, ZHANG Tinglu, ZHAO Changxin. Analysis of genotyping and 6 nucleosides' resistance of HBV in patients with chronic hepatitis B [J]. Laboratory Medicine, 2019, 34(11): 994-997.
[8]	HOU Li, YU Lu, NIU Yao, ZHANG Yuan, WANG Liang. Role of noninvasive diagnostic model for liver fibrosis in patients with chronic hepatitis B [J]. Laboratory Medicine, 2018, 33(10): 888-893.
[9]	LIANG Dongyu, HOU Yanqiang, LOU Xiaoli. Relationship of DcR3 expression with Fas expression in patients with chronic hepatitis B,liver cirrhosis and liver cancer [J]. Laboratory Medicine, 2017, 32(3): 178-181.
[10]	GE Danhong, XU Chong, YAO Yufeng. Expressions of natural killer-associated receptors on cytotoxic T lymphocyte from peripheral blood of patients with chronic hepatitis B [J]. Laboratory Medicine, 2017, 32(2): 108-113.
[11]	FENG Yueyue, WANG Lei. Progress on the correlation of traditional Chinese medicine syndromes and determination indicators in patients with chronic hepatitis B [J]. Laboratory Medicine, 2016, 31(2): 147-152.
[12]	DU Zhenhua, BAO Buhe, WANG Renjie, REN Dangli, ZHANG Minghua, LIU Jiqin. Correlation analysis on the changes of DNT cells and T lymphocyte subsets in the chronic progress of hepatitis B [J]. Laboratory Medicine, 2015, 30(7): 723-727.
[13]	LIU Weiping, YI Qin, YIN Minggang.. Establishment and assessment of the cut-off value for ALT and HBV DNA combination determination to diagnose HBeAg negative chronic active hepatitis B [J]. , 2014, 29(5): 483-487.
[14]	CAI Gang, WU Beiying, FAN Zhenjia, SHEN Qian.. Primary analysis on the function of peripheral blood HBV-specific CD8⁺T cells from patients with chronic hepatitis B [J]. , 2014, 29(1): 10-14.
[15]	DING Qingli, TANG Gusheng, HE Zhengwen, SHEN Qian, QIN Yanghua.. The proportion of Th17 cells and IL-17 expression levels in peripheral blood of patients with chronic hepatitis B and their clinical significance [J]. , 2014, 29(1): 15-20.